Transgenic Group (2342) Stock Overview
Develops, distributes, and licenses genetically modified animals and antibodies in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
2342 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Transgenic Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥272.00 |
| 52 Week High | JP¥487.00 |
| 52 Week Low | JP¥130.00 |
| Beta | 0.27 |
| 1 Month Change | -9.63% |
| 3 Month Change | -2.51% |
| 1 Year Change | 44.68% |
| 3 Year Change | -18.07% |
| 5 Year Change | -55.63% |
| Change since IPO | -87.41% |
Recent News & Updates
Is Transgenic Group (TSE:2342) A Risky Investment?
Jan 15
Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/S
Nov 19Recent updates
Is Transgenic Group (TSE:2342) A Risky Investment?
Jan 15Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/S
Nov 19Here's Why Transgenic Group (TSE:2342) Can Afford Some Debt
Jun 17There's No Escaping Transgenic Group Inc.'s (TSE:2342) Muted Revenues Despite A 33% Share Price Rise
Jun 17Little Excitement Around Transgenic Group Inc.'s (TSE:2342) Revenues
Apr 15Transgenic Group Inc.'s (TSE:2342) Share Price Is Matching Sentiment Around Its Revenues
Nov 13Improved Revenues Required Before Trans Genic Inc. (TSE:2342) Shares Find Their Feet
Apr 27Shareholder Returns
| 2342 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 0.9% |
| 1Y | 44.7% | 2.8% | 31.6% |
Return vs Industry: 2342 exceeded the JP Biotechs industry which returned 2.8% over the past year.
Return vs Market: 2342 exceeded the JP Market which returned 31.6% over the past year.
Price Volatility
| 2342 volatility | |
|---|---|
| 2342 Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in JP Market | 9.2% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 2342's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 2342's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 241 | Kenji Fukunaga | transgenic-group.co.jp |
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services.
Transgenic Group Inc. Fundamentals Summary
| 2342 fundamental statistics | |
|---|---|
| Market cap | JP¥4.53b |
| Earnings (TTM) | -JP¥770.00m |
| Revenue (TTM) | JP¥12.89b |
Is 2342 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2342 income statement (TTM) | |
|---|---|
| Revenue | JP¥12.89b |
| Cost of Revenue | JP¥10.60b |
| Gross Profit | JP¥2.30b |
| Other Expenses | JP¥3.07b |
| Earnings | -JP¥770.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -46.24 |
| Gross Margin | 17.82% |
| Net Profit Margin | -5.97% |
| Debt/Equity Ratio | 57.6% |
How did 2342 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/28 09:44 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Transgenic Group Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.